General Federal Contracts — August 01, 2026

Regeneron's cost-plus-fixed-fee contract from BARDA (HHS) for biotechnology R&D minimizes profit volatility and ensures cost recovery over 10 years through 2027, with $238.8M already outlaid. This is a competitive win under full-and-open competition, signaling strong positioning in pandemic preparedness and biodefense.

AT&T's firm-fixed-price delivery order for telephone systems at foreign posts ended March 2021, with only $27.3M outlaid of $261.1M obligated. This provides no current or future revenue contribution, limiting its investment signal.

Lockheed Martin's cost-plus-fixed-fee NASA contract for advanced technology R&D ended in August 2020, with $17.3M obligated. It is a sole-source award, but the completed status means no forward-looking insight.

Regeneron's $695.7M contract has a vague description ('IGF::OT::IGF') and 10-year duration, creating uncertainty around specific deliverables and execution milestones. Monitor outlay pace to gauge government commitment.

The digest is heavily concentrated on one active contract (Regeneron, 71% of total value), with two completed contracts providing no current revenue. This limits diversification of actionable signals.

Regeneron's BARDA contract aligns with sustained HHS investment in biodefense and pandemic preparedness, a priority under NDAA and public health funding. Potential for follow-on awards or option exercises.

The Department of State's $261.1M telecom contract (now completed) suggests ongoing need for diplomatic communications infrastructure. AT&T may compete for follow-on contracts, though no current active award.

Regeneron's $695.7M BARDA contract (10-year, cost-plus) demonstrates durable government commitment to biotechnology R&D for medical countermeasures, a priority under HHS and NDAA frameworks.

AT&T's State Department telecom contract and Lockheed Martin's NASA R&D contract are both completed, offering no current revenue. This reduces the digest's actionable signals for telecom and aerospace sectors.

{"entity" => "Regeneron Pharmaceuticals", "reason" => "Active $695.7M BARDA contract with long-term revenue visibility but vague deliverables.", "trigger" => "Future outlay announcements, contract modifications, option exercises, or R&D pipeline disclosures"}

{"entity" => "AT&T Technical Services Company", "reason" => "Completed $261.1M State Department contract; potential for follow-on telecom awards.", "trigger" => "Re-competition announcement from Department of State for foreign post telecommunications"}

{"entity" => "Lockheed Martin Corporation", "reason" => "Historical $17.3M NASA contract; monitor for re-competition of advanced technology R&D work.", "trigger" => "NASA Ames Research Center solicitation for similar R&D services"}